Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's disease

(2016) Kaitlin M. Moore et al.   NEUROBIOLOGY OF DISEASE

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models

(2015) Yvonne Bouter et al.   ACTA NEUROPATHOLOGICA

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

(2015) Robert Baranello et al.   Current Alzheimer Research

CALHM1 ion channel elicits amyloid-  clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain

(2015) V. Vingtdeux et al.   JOURNAL OF CELL SCIENCE

Clearance systems in the brain—implications for Alzheimer disease

(2015) Jenna M. Tarasoff-Conway et al.   Nature Reviews Neurology

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

(2015) Gabriela A. N. Crespi et al.   Scientific Reports

Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?

(2014) Andrew D. Watt et al.   ACTA NEUROPATHOLOGICA

Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS

(2014) Biljana Georgievska et al.   JOURNAL OF NEUROCHEMISTRY

Uncovering Effects of Ex Vivo Protease Activity during Proteomics and Peptidomics Sample Extraction in Rat Brain Tissue by Oxygen-18 Labeling

(2014) Christoph Stingl et al.   JOURNAL OF PROTEOME RESEARCH

Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β

(2013) Simon J. Henderson et al.   BRAIN

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

(2013) Aaron H. Burstein et al.   CLINICAL NEUROPHARMACOLOGY

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Enhanced Proteolytic Clearance of Plasma A  by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain A  in Mice

(2013) J. R. Walker et al.   JOURNAL OF NEUROSCIENCE

Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

(2013) Kaj Blennow et al.   NEUROPSYCHOPHARMACOLOGY

Regulation of distinct pools of amyloid β-protein by multiple cellular proteases

(2013) Malcolm A Leissring et al.   Alzheimers Research & Therapy

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment

(2012) Erik Portelius et al.   CURRENT PHARMACEUTICAL DESIGN

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?

(2011) Natalia N. Nalivaeva et al.   JOURNAL OF NEUROCHEMISTRY

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism

(2010) Niklas Mattsson et al.   BMC Neurology

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis

(2010) Francesco Mori et al.   NEUROPSYCHOPHARMACOLOGY

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

(2009) Magnus Gisslén et al.   BMC Neurology

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

(2009) N Mattsson et al.   Multiple Sclerosis Journal